[1]耿艳,徐书杭,鲁一兵,等.非编码RNA在分化型甲状腺癌分子诊断中的作用[J].国际内分泌代谢杂志,2017,37(02):101-104.[doi:10.3760/cma.j.issn.1673-4157.2017.02.008]
　Geng Yan*,Xu Shuhang,Lu Yibing,et al.Noncoding RNA in molecular diagnosis of differentiated thyroid cancer[J].International Journal of Endocrinology and Metabolism,2017,37(02):101-104.[doi:10.3760/cma.j.issn.1673-4157.2017.02.008]
点击复制

非编码RNA在分化型甲状腺癌分子诊断中的作用()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
37
期数:
2017年02期
页码:
101-104
栏目:
综述
出版日期:
2017-03-20

文章信息/Info

Title:
Noncoding RNA in molecular diagnosis of differentiated thyroid cancer
作者:
耿艳; 徐书杭; 鲁一兵; 刘超
210011 南京医科大学第二临床医学院(耿艳); 221006 徐州医学院第二附属医院内分泌科(耿艳); 210028 南京,江苏省中医药研究院,南京中医药大学附属中西医结合医院内分泌代谢病院区(徐书杭,刘超); 210011 南京医科大学第二附属医院内分泌科(鲁一兵)
Author(s):
Geng Yan*;  Xu Shuhang;  Lu Yibing;  Liu Chao.
*The Second Clinical Medical School of Nanjing Medical University, Nanjing 210011, China; Department of Endocrinology, The Second Affiliated Hospital of Xuzhou Medical College, Xuzhou 221006, China
关键词:
非编码RNA;  分化型甲状腺癌;  分子标志物;  分子诊断
Keywords:
Noncoding RNA;  Differentiated thyroid cancer;  Molecular markers;  Molecular diagnosis
DOI:
10.3760/cma.j.issn.1673-4157.2017.02.008
摘要:
分化型甲状腺癌占全部甲状腺癌的90%以上,主要包括乳头状癌和滤泡状癌。目前,细针穿刺抽吸活检是术前诊断甲状腺肿瘤的金标准,但仍存在一定的局限性,且临床上尚无理想的分子标志物用于确诊。非编码RNA是无蛋白编码功能的RNA,主要包括微小RNA(miRNA)和长链非编码RNA(lncRNA),二者在甲状腺癌的发生、发展中起重要作用,其在分化型甲状腺癌分子诊断中的作用日益受到人们的关注,有望成为甲状腺癌诊断与分类的理想标志物。
Abstract:
Differentiated thyroid cancer, which mainly includes papillary and follicular cancer, accounts for more than 90% of all thyroid cancers. Currently, the gold standard for preoperative diagnosis of thyroid tumors is fine needle aspiration biopsy which has certain limitations yet. So far, there have not been ideal molecular markers used in accurately diagnosing thyroid cancer. Noncoding RNAs, which are transcribed but do not encode proteins, largely comprise microRNAs(miRNAs)and long noncoding RNAs(lncRNAs), and play important roles in the occurrence and development of thyroid cancer. Because noncoding RNA may serve as ideal diagnostic molecular markers for thyroid cancer, its role in molecular diagnosis of differentiated thyroid cancer have attracted more attention.

参考文献/References:

[1] Haugen BR, Alexander EK, Bible KC,et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer[J].Thyroid,2016,26(1):1-133. DOI:10.1089/thy.2015.0020.
[2] Keutgen XM, Filicori F, Crowley MJ,et al. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration[J].Clin Cancer Res,2012,18(7):2032-2038. DOI: 10.1158/1078-0432.CCR-11-2487.
[3] Liu R, Xing M. TERT promoter mutations in thyroid cancer[J].Endocr Relat Cancer,2016,23(3):R143-R155. DOI: 10.1530/ERC-15-0533.
[4] Sun J, Zhang J, Lu J,et al. BRAF V600E and TERT promoter mutations in papillary thyroid carcinoma in Chinese Patients[J].PLoS One,2016,11(4):e0153319. DOI: 10.1371/journal.pone.0153319.
[5] Chrus'cik A, Lam AK. Clinical pathological impacts of micro RNAs in papillary thyroid carcinoma: a crucial review[J].Exp Mol Pathol,2015,99(3):393-398. DOI: 10.1016/j.yexmp.2015.08.013.
[6] Guo Z, Hardin H, Montemayor-Garcia C,et al. In situ hybridization analysis of miR-146b-5p and miR-21 in thyroid Nodules:diagnostic implications[J].Endocr Pathol,2015,26(2):157-163. DOI: 10.1007/s12022-015-9363-x.
[7] Lima CR, Geraldo MV, Fuziwara CS,et al. MiRNA-146b-5p upregulates migration and invasion of different papillary thyroid carcinoma cells[J].BMC Cancer,2016,16:108. DOI: 10.1186/s12885-016-2146-z.
[8] Minna E, Romeo P, De Cecco L,et al. miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma[J].Oncotarget,2014,5(9):2513-2528.DOI: 10.18632/oncotarget.1830.
[9] Liu L, Wang J, Li X,et al. MiR-204-5p suppresses cell proliferation by inhibiting IGFBP5 in papillary thyroid carcinoma[J].Biochem Biophys Res Commun,2015,457(4):621-626. DOI: 10.1016/j.bbrc.2015.01.037.
[10] Dettmer M, Perren A, Moch H,et al. Comprehensive microRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma[J].Thyroid,2013,23(11):1383-1389. DOI: 10.1089/thy.2012.0632.
[11] Suresh R, Sethi S, Ali S,et al. Differential expression of microRNAs in papillary thyroid carcinoma and their role in racial disparity[J].J Cancer Sci Ther,2015,7(5):145-154.DOI: 10.4172/1948-5956.1000340.
[12] Yu S, Liu Y, Wang J,et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma[J].J Clin Endocrinol Metab,2012,97(6):2084-2092. DOI: 10.1210/jc.2011-3059.
[13] Li M, Song Q, Li H,et al. Circulating miR-25-3p and miR-451a may be potential biomarkers for the diagnosis of papillary thyroid carcinoma[J].PLoS One,2015,10(7):e0132403. DOI: 10.1371/journal.pone.0132403. eCollection 2015.
[14] Lee YS, Lim YS, Lee JC,et al. Differential expression levels of plasma-derived miR-146b and miR-155 in papillarythyroid cancer[J].Oral Oncol,2015,51(1):77-83. DOI: 10.1016/j.oraloncology.2014.10.006.
[15] Cantara S, Pilli T, Sebastiani G,et al. Circulating miRNA95 and miRNA190 are sensitive markers for the differential diagnosis of thyroid nodules in a Caucasian population[J].J Clin Endocrinol Metab,2014,99(11):4190-4198. DOI: 10.1210/jc.2014-1923.
[16] Dettmer M, Vogetseder A, Durso MB,et al. MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas[J].J Clin Endocrinol Metab,2013,98(1):E1-E7. DOI: 10.1210/jc.2012-2694.
[17] Weber F, Teresi RE, Broelsch CE,et al. A limited set of human microRNA is deregulated in follicular thyroid carcinoma[J].J Clin Endocrinol Metab,2006,91(9):3584-3591. DOI: 10.1210/jc.2006-0693.
[18] Rossing M, Borup R, Henao R,et al. Down-regulation of microRNAs controlling tumourigenic factors in follicular thyroid carcinoma[J].J Mol Endocrinol,2012,48(1):11-23. DOI: 10.1530/JME-11-0039.
[19] Wojtas B, Ferraz C, Stokowy T,et al. Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas[J].Mol Cell Endocrinol,2014,388(1-2):1-9. DOI: 10.1016/j.mce.2014.02.011.
[20] Yoon H, He H, Nagy R,et al. Identification of a novel noncoding RNA gene, NAMA, that is downregulated in papillary thyroid carcinoma with BRAF mutation and associated with growth arrest[J].Int J Cancer,2007,121(4):767-775.DOI: 10.1002/ijc.22701.
[21] Wang Y, Guo Q, Zhao Y,et al. BRAF-activated long non-coding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma[J].Oncol Lett,2014,8(5):1947-1952. DOI: 10.3892/ol.2014.2487.
[22] Jendrzejewski J, Thomas A, Liyanarachchi S,et al. PTCSC3 is involved in papillary thyroid carcinoma development by modulating S100A4 gene expression[J].J Clin Endocrinol Metab,2015,100(10):E1370-E1377. DOI: 10.1210/jc.2015-2247.
[23] Fan M, Li X, Jiang W,et al. A long non-coding RNA, PTCSC3, as a tumor suppressor and a target of miRNAs in thyroid cancer cells[J].Exp Ther Med,2013,5(4):1143-1146. DOI:10.3892/etm.2013.933.
[24] Zheng H, Wang M, Jiang L, et al. BRAF-activated long noncoding RNA modulates papillary thyroid carcinoma cell proliferation through regulating thyroid stimulating hormone receptor[J].Cancer Res Treat,2016,48(2):698-707. DOI: 10.4143/crt.2015.118.
[25] Lan X, Zhang H, Wang Z,et al. Genome-wide analysis of long noncoding RNA expression profile in papillary thyroid carcinoma[J].Gene,2015,569(1):109-117.DOI:10.1016/j.gene.2015.05.046.
[26] Lan X, Sun W, Zhang P,et al. Downregulation of long noncoding RNA NONHSAT037832 in papillary thyroid carcinoma and its clinical significance[J].Tumour Biol,2016,37(5):6117-6123.DOI:10.1007/s13277-015-4461-4.

相似文献/References:

[1]李静,李曙光,乐岭.二甲双胍抑制分化型甲状腺癌的作用及机制[J].国际内分泌代谢杂志,2021,41(01):28.[doi:10.3760/cma.j.cn121383-20200514-05032]
　Li Jing,Li Shuguang,Yue Ling..Effects and mechanisms of metformin on differentiated thyroid cancer[J].International Journal of Endocrinology and Metabolism,2021,41(02):28.[doi:10.3760/cma.j.cn121383-20200514-05032]
[2].甲状腺结节和分化型甲状腺癌诊治指南(第二版)[J].国际内分泌代谢杂志,2023,43(02):149.[doi:10.3760/cma.j.cn311282-20221023-00589]
　Chinese Society of Endocrinology,Thyroid and Metabolism Surgery Group of the Chinese Society of Surgery,China Anti-Cancer Association,et al.Guidelines for the Diagnosis and Management of Thyroid Nodules and Differentiated Thyroid Cancer(Second Edition)[J].International Journal of Endocrinology and Metabolism,2023,43(02):149.[doi:10.3760/cma.j.cn311282-20221023-00589]

备注/Memo

备注/Memo:
基金项目:江苏省重点研发计划(社会发展)项目(BE2015723) 通信作者:鲁一兵,Email:luyibing2004@126.com; 刘超,Email:liuchao@nfmcn.com
更新日期/Last Update: 2017-03-20